# Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery

> **NCT00357617** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Centre Hospitalier Universitaire Vaudois** · enrollment: 24 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** celecoxib
- **GENETIC:** microarray analysis
- **GENETIC:** protein expression analysis
- **OTHER:** immunoenzyme technique
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** biopsy
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** neoadjuvant therapy

## Key facts

- **NCT ID:** NCT00357617
- **Lead sponsor:** Centre Hospitalier Universitaire Vaudois
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2010-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00357617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00357617, "Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00357617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*